Revance Therapeutics Inc (RVNC)
3.95
+0.18
(+4.77%)
USD |
NASDAQ |
May 03, 16:00
3.945
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Enterprise Value: 586.83M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 586.83M |
| May 02, 2024 | 568.07M |
| May 01, 2024 | 570.67M |
| April 30, 2024 | 551.39M |
| April 29, 2024 | 559.73M |
| April 26, 2024 | 529.51M |
| April 25, 2024 | 518.04M |
| April 24, 2024 | 547.22M |
| April 23, 2024 | 556.60M |
| April 22, 2024 | 554.52M |
| April 19, 2024 | 569.11M |
| April 18, 2024 | 570.15M |
| April 17, 2024 | 567.02M |
| April 16, 2024 | 572.24M |
| April 15, 2024 | 588.91M |
| April 12, 2024 | 605.58M |
| April 11, 2024 | 637.89M |
| April 10, 2024 | 634.76M |
| April 09, 2024 | 663.94M |
| April 08, 2024 | 638.93M |
| April 05, 2024 | 634.76M |
| April 04, 2024 | 634.76M |
| April 03, 2024 | 649.35M |
| April 02, 2024 | 645.19M |
| April 01, 2024 | 668.11M |
| Date | Value |
|---|---|
| March 28, 2024 | 687.91M |
| March 27, 2024 | 690.00M |
| March 26, 2024 | 664.99M |
| March 25, 2024 | 659.78M |
| March 22, 2024 | 682.70M |
| March 21, 2024 | 716.05M |
| March 20, 2024 | 703.55M |
| March 19, 2024 | 688.96M |
| March 18, 2024 | 690.00M |
| March 15, 2024 | 728.04M |
| March 14, 2024 | 741.06M |
| March 13, 2024 | 802.55M |
| March 12, 2024 | 830.17M |
| March 11, 2024 | 827.56M |
| March 08, 2024 | 801.51M |
| March 07, 2024 | 817.14M |
| March 06, 2024 | 835.90M |
| March 05, 2024 | 748.57M |
| March 04, 2024 | 710.64M |
| March 01, 2024 | 790.91M |
| February 29, 2024 | 805.03M |
| February 28, 2024 | 674.47M |
| February 27, 2024 | 678.00M |
| February 26, 2024 | 677.12M |
| February 23, 2024 | 659.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
198.56M
Minimum
Jun 10 2019
3.267B
Maximum
May 09 2023
1.352B
Average
1.287B
Median
Aug 11 2020
Enterprise Value Benchmarks
| AbbVie Inc | 345.20B |
| Alnylam Pharmaceuticals Inc | 17.92B |
| Ionis Pharmaceuticals Inc | 5.073B |
| Madrigal Pharmaceuticals Inc | 4.055B |
| Vertex Pharmaceuticals Inc | 92.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.70M |
| Revenue (Quarterly) | 69.80M |
| Total Expenses (Quarterly) | 123.22M |
| EPS Diluted (Quarterly) | -0.63 |
| Gross Profit Margin (Quarterly) | 74.97% |
| Profit Margin (Quarterly) | -79.80% |
| Earnings Yield | -96.20% |
| Normalized Earnings Yield | -74.36 |